

**NAME: Huei Wang**

**PHOTO**



**[PRESENT POSITIONS]**

**Biostatistics Director, Amgen Inc**

**[FORMER POSITIONS]**

**Biostatistical Senior Manager / Principal Biostatistician II, Amgen Inc**

**[DEGREES]**

PhD Biostatistics, School of Public Health, University of South Carolina, Columbia, SC

**[FIELDS OF MAJOR STATISTICAL ACTIVITIES]**

- The planning committee of the ASA local chapter [The Orange County Long Beach ASA (OCLBASA)] which plans annual Orange County Biostatistics Symposium.
- Amgen CfDA(Center for Design and Analysis) sponsorship and donation planning committee for statistical-related conferences, meetings, and related-activities.

**[SELECTED PUBLICATIONS]**

Yumiko Asami, MS; Yutaka Noguchi, MS; Huei Wang, PhD; Ying Zhou, PhD; Denise Smith, MS. A proposed process for the implementation of statistical analyses and regulatory responses for global new drug applications, including Japan-specific analyses and preparations to PMDA. 2020 accepted by *DIA*

Yumiko Asami, MS, Huei Wang, PhD, Chunlei Ke, PhD, Li Zhu, PhD, Qi Jiang, PhD, Tomonori Yamasaki, MS, Takayoshi Ichikawa, R.Ph, Koji Hirata, BS. Visualization of the non-inferiority margin for the synthesis method and its utilization in PMDA submissions. 2020 under review and submitted to *Therapeutic Innovation & Regulatory Science*.

Baris Gencer, MD, François Mach, MD; Sabina A. Murphy, MPH; Gaetano M. De Ferrari, MD; Kurt Huber, MD; Basil S. Lewis, MD; Jorge Ferreira, MD; Christopher E. Kurtz, MD; Huei Wang, PhD; Narimon Honarpour, MD; Anthony C. Keech, MD; Peter S. Sever, MD; Terje R. Pedersen, MD; Marc S. Sabatine, MD, MPH; Robert P. Giugliano, MD, SM. Evolocumab and Cardiovascular Outcomes in Patients with Recent Myocardial Infarction: A Prespecified Analysis from the FOURIER trial. *JAMA Cardiol.* May 20, 2020.

Baris Gencer, MD, François Mach, MD, Jianping Guo, MS, KyungAh Im, PHD, Andrea Ruzza, MD, PHD, Huei Wang, PHD, Christopher E. Kurtz, MD, Terje Rolf Pedersen, MD, PHD, Anthony C. Keech, MD, Brian R. Ott, MD, Marc S. Sabatine, MD, MPH, Robert P. Giugliano, MD, SM, on behalf of the FOURIER Investigators. Cognition After Lowering LDL Cholesterol With Evolocumab. *J Am Coll Cardiol* 2020. May 12, 2020

Robert P. Giugliano, MD, SM; Terje R. Pedersen, MD; Jeffrey L. Saver, MD; Peter S. Sever, PhD; Anthony C. Keech, MD; Erin A. Bohula, MD, DPhil; Sabina A. Murphy, MPH; Scott M. Wasserman, MD; Narimon Honarpour, MD; Huei Wang, PhD; Armando Lira Pineda, MD; Marc S. Sabatine, MD, MPH; on behalf of the FOURIER Investigators. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. *Stroke.* 2020; 51:1546-1554

Nicholas A. Marston, MD; Frederick K. Kamanu, PhD; Francesco Nordio, PhD; Yared Gurmu, PhD; Carolina Roselli, MS; Peter S. Sever, PhD; Terje R. Pedersen, MD; Anthony C. Keech, MD; Huei Wang, PhD; Armando Lira Pineda, MD; Robert P. Giugliano, MD; Steven A. Lubitz, MD, MPH; Patrick T. Ellinor, MD, PhD; Marc S. Sabatine, MD, MPH; Christian T. Ruff, MD, MPH. Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score Results From the FOURIER Trial. *Circulation.* 2019; 140:00–00

Robert P. Giugliano, François Mach, Kenton Zavitz, Christopher Kurtz, Jingjing Schneider, Huei Wang, Anthony Keech, Terje R. Pedersen, Marc S. Sabatine, Peter S. Sever, Narimon Honarpour, Scott M. Wasserman, Brian R. Ott on behalf of the EBBINGHAUS Investigators. Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy—A cognitive study of patients enrolled in the FOURIER trial. *Clinical Cardiology* 2017; 40(2):59–65

Marc S. Sabatine, M.D., M.P.H., Robert P. Giugliano, M.D., Anthony C. Keech, M.D., Narimon Honarpour, M.D., Ph.D., Stephen D. Wiviott, M.D., Sabina A. Murphy, M.P.H., Julia F. Kuder, M.A., Huei Wang, Ph.D., Thomas Liu, Ph.D., Scott M. Wasserman, M.D., Peter S. Sever, Ph.D., F.R.C.P., and Terje R. Pedersen, M.D. et al., for the FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med* 2017; 376:1713-1722

## **[ICSA ACTIVITIES]**

NA – I am a new member starting in 2020.

## **[PROFESSIONAL COMMITTEES]**

- A member of a cross-industry committee to review and provide feedback and comments on the FDA and EMA draft guidelines on multiplicity.
- The Committee chair of Amgen GBS good practice guideline on multiplicity
- A member of Amgen review committee on statistical related draft regulatory guidelines

## **[HONORS AND AWARDS]**

NA

## **[STATEMENT]**

### **Two simple goals:**

- Volunteer and serve the organizations to promote the theory and applications of statistical disciplines as well as to broaden applications of statistical techniques which creates benefits to science & researches as well as impacts on human lives.
- Serve patients. As a statistician in the pharmaceutical industry for many years, our daily hard works will impact millions of patients' lives every day which motives me to go to work. Statisticians are vital for f clinical trial design, execution, analysis, and interpretation & clinical trial applications of statistical techniques benefit clinical trial development and bring a new product to the needed patients sooner.